|
gptkbp:instanceOf
|
antineoplastic agent
|
|
gptkbp:administeredBy
|
radiotherapy
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01AX03
|
|
gptkbp:brand
|
gptkb:Temodal
gptkb:Temodar
|
|
gptkbp:CASNumber
|
85622-93-1
|
|
gptkbp:category
|
antineoplastic agent
imidazotetrazine derivative
|
|
gptkbp:chemicalFormula
|
C6H6N6O2
|
|
gptkbp:contraindication
|
hypersensitivity to temozolomide
hypersensitivity to dacarbazine
|
|
gptkbp:developedBy
|
gptkb:Aston_University
|
|
gptkbp:discoveredBy
|
gptkb:Malcolm_Stevens
|
|
gptkbp:eliminationHalfLife
|
1.8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1987
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Temozolomide
|
|
gptkbp:KEGGID
|
D06053
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA methylation
|
|
gptkbp:MeSH_ID
|
D000068879
|
|
gptkbp:metabolism
|
non-enzymatic hydrolysis
|
|
gptkbp:molecularWeight
|
194.15 g/mol
|
|
gptkbp:origin
|
gptkb:United_Kingdom
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL606
5201
5394
DB00853
|
|
gptkbp:riskFactor
|
immunosuppression
teratogenicity
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
constipation
fatigue
headache
myelosuppression
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:synonym
|
gptkb:NSC_362856
gptkb:SCH_52365
gptkb:TMZ
|
|
gptkbp:UNII
|
JEP0YGT94R
|
|
gptkbp:usedFor
|
gptkb:glioblastoma_multiforme
gptkb:anaplastic_astrocytoma
malignant glioma
|
|
gptkbp:bfsParent
|
gptkb:C10483
|
|
gptkbp:bfsLayer
|
7
|